Late Breaking Abstract - Real-World Characteristics of Patients Receiving Dupilumab in Routine Clinical Practice in a Multinational, Non-Interventional Study (ProVENT)
M. Lommatzsch (Rostock, Germany), S. Korn (Mainz, Germany), O. Schmidt (Koblenz, Germany), H. Timmermann (Hamburg, Germany), H. Watz (Grosshansdorf, Germany), A. Radwan (Tarrytown, United States of America), L. De Prado-Gomez (Reading, United States of America), A. Atenhan (Berlin, Germany), S. Barbus (Frankfurt, Germany), M. Thakur (Berlin, Germany)
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Lommatzsch (Rostock, Germany), S. Korn (Mainz, Germany), O. Schmidt (Koblenz, Germany), H. Timmermann (Hamburg, Germany), H. Watz (Grosshansdorf, Germany), A. Radwan (Tarrytown, United States of America), L. De Prado-Gomez (Reading, United States of America), A. Atenhan (Berlin, Germany), S. Barbus (Frankfurt, Germany), M. Thakur (Berlin, Germany). Late Breaking Abstract - Real-World Characteristics of Patients Receiving Dupilumab in Routine Clinical Practice in a Multinational, Non-Interventional Study (ProVENT). 564
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: